专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2003057911A3 SINGLE NUCLEOTIDE POLYMORPHISMS PREDICTING CARDIOVASCULAR DISEASE AND MEDICATION EFFICACY 审中-公开
公开(公告)号：WO2003057911A3
公开(公告)日：2003-07-17
申请号：PCT/EP2003/000060
申请日：2003-01-07
申请人： BAYER HEALTHCARE AG , STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald
发明人： STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald
IPC分类号： C12N15/12
摘要： The present invention relates to isolated polynucleotides encoding a cardiovascular associated (CA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease, the polynucleotide is selected from the group comprising:SEQ ID 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for CA gene polypeptide and with or without the CA gene promoter sequence.The invention also provides diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. The invention provides further polymorphic sequences and other genes.

2. 发明申请

WO2006008045A1 SINGLE NUCLEOTIDE POLYMORPHISMS AS PROGNOSTIC TOOL TO DIAGNOSE ADVERSE DRUG REACTIONS (ADR) AND DRUG EFFICACY 审中-公开
标题翻译：单核苷酸多态性作为诊断工具诊断不良药物反应（ADR）和药物效力
公开(公告)号：WO2006008045A1
公开(公告)日：2006-01-26
申请号：PCT/EP2005/007600
申请日：2005-07-13
申请人： BAYER HEALTHCARE AG , STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald
发明人： STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising: SEQ ID 1-131 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence. Sequences: The sequence section contains all phenotype associated (‘PA’) SNPs and adjacent genomic sequences. The position of the polymorphisms that were used for the association studies (‘baySNP’) is indicated. Sometimes additional variations are found in the surrounding genomic sequence, that are marked by it’s respective IUPAC code. Although those surrounding SNPs were not explicitly analyzed, they likely exihibit a similar association to a phenotype as the baySNP (due to linkage disequillibrium, Reich D.E. et al. Nature 411, 199-204, 2001).
摘要翻译：本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否有患上药物反应风险的抗体或人类受试者是高反应者还是低反应者他汀类药物或代谢物。本发明提供了进一步的诊断方法和试剂盒，包括确定人受试者是否处于心血管疾病风险的抗体。本发明还提供了多态序列和其他基因。本发明还涉及编码可用于鉴定治疗剂并用于制备治疗心血管疾病或影响药物应答的药物的方法中的表型相关（PA）基因多肽的分离的多核苷酸，所述多核苷酸选自SEQ ID NO： ID 1-131，其具有等位基因变异，如包含在功能性周围的序列部分中所示，如PA基因多肽的全长cDNA并具有或不具有PA基因启动子序列。序列：序列部分包含所有表型相关（'PA'）SNP和相邻基因组序列。指出用于关联研究（'baySNP'）的多态性的位置。有时在周围的基因组序列中会发现额外的变化，它们由相应的IUPAC代码标记。尽管周围的SNP没有被明确分析，但它们可能与baySNP（由于连锁不平衡，Reich D.E.等，Nature 411,199-204,2001）具有类似的表型关联。

3. 发明申请

WO2003072813A2 SINGLE NUCLEOTIDE POLYMORPHISMS PREDICTING ADVERSE DRUG REACTIONS AND MEDICATION EFFICACY 审中-公开
标题翻译：单核苷酸多态性预测不良药物反应和药物效能
公开(公告)号：WO2003072813A2
公开(公告)日：2003-09-04
申请号：PCT/EP2003/001514
申请日：2003-02-14
申请人： BAYER AKTIENGESELLSCHAFT , STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald
发明人： STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising:SEQ ID 1-80 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence.
摘要翻译：本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否有患上药物反应风险的抗体或人类受试者是高反应者还是低反应者他汀类药物或代谢物。本发明提供了进一步的诊断方法和试剂盒，包括确定人受试者是否处于心血管疾病风险的抗体。本发明进一步涉及编码表型相关（PA）基因多肽的分离的多核苷酸，其用于鉴定治疗剂并可用于制备治疗心血管疾病或影响药物反应的药物的方法所述多核苷酸选自SEQ ID 1-80，其具有如包含在功能性周围的序列部分中所示的等位变异，如PA基因多肽的全长cDNA并具有或不具有PA基因启动子序列。

4. 发明申请

WO2003029486A2 SINGLE NUCLEOTIDE POLYMORPHISMS PREDICTING CARDIOVASCULAR DISEASE 审中-公开
标题翻译：单核苷酸多态性预测心血管疾病
公开(公告)号：WO2003029486A2
公开(公告)日：2003-04-10
申请号：PCT/EP2002/010843
申请日：2002-09-27
申请人： BAYER AKTIENGESELLSCHAFT , STROPP, Udo , SCHWERS, Stephan , REIFENBERGER, Elke , KALLABIS, Harald
发明人： STROPP, Udo , SCHWERS, Stephan , REIFENBERGER, Elke , KALLABIS, Harald
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , A61K38/00 , A61K48/00 , C12N9/14 , C12Q2600/156 , C12Y306/03009
摘要： The present invention relates to an isolated polynucleotide encoding a Na+/K+ ATPase polypeptide useful in methods to identify therapeutic agents useful for treating cardiovascular diseases, the polynucleotide is selected from the group consisting of:SEQ ID 4 and SEQ ID 5 (baySNP-1765) with allelic variation G in position 240 contained in a functional surrounding like full length cDNA for Na+/K+ ATPase and with or without the Na+/K+ ATPase promotor sequence; and SEQ ID 4 and SEQ ID 5 (baySNP-1765) with allelic variation A in position 240 contained in a functional surrounding like full length cDNA for Na+/K+ ATPase and with or without the Na+/K+ ATPase promotor sequence.The invention also provides diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. The invention provides further polymorphic sequences and other genes.
摘要翻译：本发明涉及用于鉴定可用于治疗心血管疾病的治疗剂的方法中的编码Na + / K + ATP酶多肽的分离的多核苷酸，所述多核苷酸选自SEQ ID NO：4和SEQ ID NO：4。 SEQ ID NO：5（baySNP-1765），其具有包含在功能性周围的等位基因变异G，如Na + / K + ATP酶的全长cDNA和有或没有Na + / K + ATP酶启动子序列; 和具有包含于功能性位点240中的等位基因变异A的SEQ ID 4和SEQ ID 5（baySNP-1765），如Na + / K + ATP酶的全长cDNA和具有或不具有Na + / K + ATP酶启动子序列。本发明还提供诊断方法和试剂盒，包括确定人类受试者是否有心血管疾病风险的抗体。本发明提供了进一步的多态性序列和其他基因。

5. 发明申请

WO2007079875A2 VERFAHREN ZUR IDENTIFIZIERUNG VON PREDIKTIVEN BIOMARKERN AUS PATIENTENDATEN 审中-公开
标题翻译：一种用于识别的生物标志物预测OFF病人数据
公开(公告)号：WO2007079875A2
公开(公告)日：2007-07-19
申请号：PCT/EP2006/011896
申请日：2006-12-11
申请人： BAYER TECHNOLOGY SERVICES GMBH , SCHUPPERT, Andreas , BURGHAUS, Rolf , VON TÖRNE, Christian , SCHWERS, Stephan , STROPP, Ugo , KALLABIS, Harald
发明人： SCHUPPERT, Andreas , BURGHAUS, Rolf , VON TÖRNE, Christian , SCHWERS, Stephan , STROPP, Ugo , KALLABIS, Harald
IPC分类号： G06F19/00
CPC分类号： G06F19/18 , G06Q50/24
摘要： Verfahren zur Entwicklung eines Biomarkers zur Prognose des Ergebnisses einer therapeutischen Behandlung anhand von Daten klinischer Studien, wobei die von der Therapie unveränderten Daten in diagnostischen und genomischen Parameter geteilt werden, und der Marker durch eine Kombination von Parametern definiert wird, dadurch gekennzeichnet, dass die maximale Anzahl von Parameter zu Definition des Markers und hiermit die maximale Komplexität des Systems von Anfang an festgelegt wird, die Suche nach definierenden Parametern durch sequenzielle Kombination von klinischen Parametern (=z-Parameter) und/oder genomischen Parameter (=x-Parameter) erfolgt.
摘要翻译：一种用于生物标志物的开发过程中，预测治疗性治疗的基于临床试验数据，其中，从所述的治疗数据的不变分为诊断和基因组参数的结果，而标记是由参数的组合来定义，其特征在于，最大的参数数量，以限定所述标记和兹从开始了系统的最大复杂度被设定，搜索是通过临床参数（= Z-参数）和/或基因组参数（= X-参数）的顺序组合定义的参数。

6. 发明申请

WO2007071382A2 METHOD FOR THE PREDICTION OF ADVERSE DRUG RESPONSES 审中-公开
标题翻译：预防药物不良反应的方法
公开(公告)号：WO2007071382A2
公开(公告)日：2007-06-28
申请号：PCT/EP2006/012265
申请日：2006-12-19
申请人： BAYER HEALTHCARE AG , SCHWERS, Stephan , STROPP, Udo , KALLABIS, Harald , SCHUPPERT, Andreas , BURGHAUS, Rolf , VON TÖRNE, Christian , SCHMITZ, Gerd
发明人： SCHWERS, Stephan , STROPP, Udo , KALLABIS, Harald , SCHUPPERT, Andreas , BURGHAUS, Rolf , VON TÖRNE, Christian , SCHMITZ, Gerd
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q1/42 , C12Q1/50 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172 , G01N33/92
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a SADR gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat statin induced adverse drug reactions (SADR), the polynucleotide is selected from the group comprising: SEQ ID 1-35 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for SADR gene polypeptide and with or without the SADR gene promoter sequence.
摘要翻译：本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否存在药物反应不利的风险的抗体。本发明还提供了多态序列和其他基因。本发明还涉及编码SADR基因多肽的分离的多核苷酸，其用于鉴定治疗剂并可用于制备治疗他汀类药物诱导的不良药物反应（SADR）的药物的方法中，所述多核苷酸选自SEQ ID No.1 -35具有等位基因变异，如包含在功能性周围的序列部分中所示，如SADR基因多肽的全长cDNA并具有或不具有SADR基因启动子序列。

7. 发明申请

WO2004018708A3 GENETIC POLYMORPHISMS SENSITIVELY PREDICTING ADVERSE DRUG REACTIONS (ADR) AND DRUG EFFICACY 审中-公开
标题翻译：遗传多态性敏感预测不良药物反应（ADR）和药物效能
公开(公告)号：WO2004018708A3
公开(公告)日：2004-08-26
申请号：PCT/EP0308298
申请日：2003-07-28
申请人： BAYER HEALTHCARE AG , SCHWERS STEPHAN , KALLABIS HARALD , REIFENBERGER ELKE , STROPP UDO , SCHMITZ GERD
发明人： SCHWERS STEPHAN , KALLABIS HARALD , REIFENBERGER ELKE , STROPP UDO , SCHMITZ GERD
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising: SEQ ID 1-21 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence.
摘要翻译：本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否有患上药物反应风险的抗体或人类受试者是高反应者还是低反应者他汀类药物或代谢物。本发明提供了进一步的诊断方法和试剂盒，包括确定人受试者是否处于心血管疾病风险的抗体。本发明进一步涉及编码表型相关（PA）基因多肽的分离的多核苷酸，其用于鉴定治疗剂并可用于制备治疗心血管疾病或影响药物反应的药物的方法所述多核苷酸选自如SEQ ID 1-21所示的组，其具有等位基因变异，如包含在功能性周围的序列部分中所示，如PA基因多肽的全长cDNA并具有或不具有PA基因启动子序列。

8. 发明申请

WO2004067774A2 SINGLE NUCLEOTIDE POLYMORPHISMS AS PREDICTIVE DIAGNOSTICS FOR ADVERSE DRUG REACTIONS (ADR) AND DRUG EFFICACY 审中-公开
标题翻译：单核苷酸多态性作为不良药物反应（ADR）和药物效力的预测诊断
公开(公告)号：WO2004067774A2
公开(公告)日：2004-08-12
申请号：PCT/EP2004/000539
申请日：2004-01-23
申请人： BAYER HEALTHCARE AG , STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald
发明人： STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald
IPC分类号： C12Q1/68
CPC分类号： G01N33/5091 , C12Q1/6883 , C12Q2600/156 , G01N33/5008 , G01N33/502 , G01N33/6893 , G01N2800/52
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.
摘要翻译：本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否有患上药物反应风险的抗体或人类受试者是高反应者还是低反应者他汀类药物或代谢物。本发明提供了进一步的诊断方法和试剂盒，包括确定人受试者是否处于心血管疾病风险的抗体。本发明还提供了多态序列和其他基因。

9. 发明申请

WO2004018708A2 GENETIC POLYMORPHISMS SENSITIVELY PREDICTING ADVERSE DRUG REACTIONS (ADR) AND DRUG EFFICACY 审中-公开
标题翻译：遗传多态性对预后不良反应（ADR）和药物有效性的敏感性预测
公开(公告)号：WO2004018708A2
公开(公告)日：2004-03-04
申请号：PCT/EP2003/008298
申请日：2003-07-28
申请人： BAYER HEALTHCARE AG , SCHWERS, Stephan , KALLABIS, Harald , REIFENBERGER, Elke , STROPP, Udo , SCHMITZ, Gerd
发明人： SCHWERS, Stephan , KALLABIS, Harald , REIFENBERGER, Elke , STROPP, Udo , SCHMITZ, Gerd
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising: SEQ ID 1-21 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence.
摘要翻译：本发明提供了诊断方法和试剂盒，包括寡核苷酸和/或多核苷酸或衍生物，还包括确定人受试者在他汀类药物治疗后是否有风险发生药物不良反应的抗体，或者人受试者是否他汀类药物的高或低反应者或良好或不好的代谢者。本发明提供了进一步的诊断方法和试剂盒，其包括确定人受试者是否有心血管疾病风险的抗体。本发明还提供了多态性序列和其他基因。本发明进一步涉及编码表型相关（PA）基因多肽的分离的多核苷酸，其用于鉴定治疗剂并用于制备治疗心血管疾病或影响药物应答的药物的方法，所述多核苷酸选自包含具有等位基因变异的SEQ ID1-121，所述等位基因变异包含在功能性包含的序列部分中，如PA基因多肽的全长cDNA和有或没有PA基因启动子序列。

10. 发明申请

WO02097127A3 GENES AND PROTEINS FOR PREVENTION, PREDICTION, DIAGNOSIS, PROGNOSIS AND TREATMENT OF CHRONIC LUNG DISEASE 审中-公开
标题翻译：预防，预防，诊断，预防和治疗慢性肺疾病的基因和蛋白质
公开(公告)号：WO02097127A3
公开(公告)日：2003-08-21
申请号：PCT/EP0205835
申请日：2002-05-28
申请人： BAYER AG , OELLERS NADJA , GEHRMANN MATHIAS , KALLABIS HARALD , HALL RODERICK , SCHULZE THOMAS , KROEGEL CLAUS
发明人： OELLERS NADJA , GEHRMANN MATHIAS , KALLABIS HARALD , HALL RODERICK , SCHULZE THOMAS , KROEGEL CLAUS
IPC分类号： A61K48/00 , C07K14/47 , C12Q1/68 , G01N33/48
CPC分类号： C12Q1/6883 , C12Q2600/158
摘要： Genes that are differentially expressed in lung tissue of COPD patients versus lungs of normal people are disclosed. The genes provide novel methods for the prevention, prediction, diagnosis, prognosis and treatment of chronic lung disease.
摘要翻译：公开了在COPD患者的肺组织中与正常人的肺部差异表达的基因。这些基因为慢性肺部疾病的预防，预测，诊断，预后和治疗提供了新的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式